Metabolomics Market Expansion at 11.2% CAGR Through 2031 as North America Leads with 40% Share Supported by Thermo Fisher Scientific Agilent Technologies and Waters Corporation

According to the Metabolomics Market report by DataM Intelligence, the market is projected to expand at a CAGR of approximately 11.2% from 2024 to 2031.

Growth is supported by increasing demand across key applications such as drug discovery, personalized medicine, toxicology testing, nutrigenomics, and biomarker identification, driven by rising investments in pharmaceutical and biotech R&D, expanding adoption of advanced analytical technologies (like LC-MS, GC-MS, and NMR), and the growing focus on precision healthcare and systems biology. The market benefits from heightened research funding, technological advancements, and the integration of bioinformatics tools that improve data analysis and interpretation, fostering broad adoption across clinical, research, and industrial sectors globally. North America commands the largest share, while the Asia Pacific region is poised for rapid growth over the forecast period.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/metabolomics-market?sindhuri

Metabolomics Market: Competitive Intelligence
Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, Shimadzu Corporation, Human Metabolome Technologies, Inc., Metabolon Inc., Bio-Rad Laboratories, LECO Corporation, and others.

The Metabolomics Market is strongly driven by leading players such as Thermo Fisher Scientific, Agilent Technologies, Danaher, Waters Corporation, and Bruker Corporation, who provide advanced analytical instruments, software, reagents, and services for comprehensive metabolite profiling. Their integrated platforms spanning liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR), and bioinformatics tools enable highly accurate identification and quantification of small molecule metabolites for applications in drug discovery, personalized medicine, toxicology testing, nutrigenomics, and clinical diagnostics. Rising demand for precision healthcare and increased adoption of metabolomics by pharmaceutical, biotech, and academic research sectors are key growth drivers.

These companies' complementary strengths are high-performance analytical technologies from Thermo Fisher, Agilent, Danaher, and Waters; specialized solutions from Bruker and Shimadzu; and focused metabolomics research and data interpretation capabilities from Human Metabolome Technologies and Metabolon are enhancing competitive positioning. Strategic focus areas include automation of workflows, advanced data analytics, hybrid analytical platforms, expanded clinical applications, and collaborations aligned with R&D and personalized medicine initiatives, strengthening competitiveness across research and clinical segments worldwide.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/metabolomics-market?sindhuri

Recent Key Developments - United States
✅ June 2025: Thermo Fisher Scientific unveiled next-generation mass spectrometry platforms the Orbitrap Astral Zoom and Orbitrap Excedion Pro at the ASMS 2025 conference, enhancing analytical performance (speed, sensitivity, accuracy) to support advanced metabolomics and biopharma applications.
✅ April 2025: Metabolon launched a new microbiome research solution that integrates a comprehensive microbiome metabolite panel with metagenomics sequencing and advanced bioinformatics tools for multiomics research, enabling deeper insights into microbiome-host metabolic interactions.
✅ 2025: Biocrates Life Sciences introduced targeted metabolomics kits focused on clinical research applications, expanding tool availability for precise metabolic profiling and biomarker validation.

Recent Key Developments - Global
✅ 2025 - Market Growth Trends: The global metabolomics market reached significant valuation in 2025 and is projected to grow rapidly into 2026 and beyond, with estimates placing global industry size around USD 4.7 billion in 2026 and accelerating toward double-digit valuations by 2035.
✅ Ongoing Trend - Integration with AI and Bioinformatics: Across regions, there's growing adoption of AI-guided data analytics and cloud-based bioinformatics platforms in metabolomics workflows, improving large-dataset interpretation, predictive modeling, and cross-study comparability.
✅ Multiomics Expansion: Key research and commercial initiatives are emphasizing integration of metabolomics with genomics, proteomics, and microbiome sequencing, fostering comprehensive multiomics approaches for precision medicine and drug discovery globally

✅ 1. M&A (Mergers & Acquisitions)
Bruker Corporation acquires biocrates life sciences ag
In June 2025, Bruker Corporation announced the acquisition of biocrates life sciences ag, a leader in quantitative, mass-spectrometry-based metabolomics kits, assays, software, and services. This strategic move expands Bruker's multiomics portfolio by integrating standardized metabolomics workflows alongside proteomics and other omics solutions.

✅ 2. New Product Launches & Technology Releases
biocrates launches the MxP® Quant 1000 metabolomics kit
At Metabolomics 2025 (June 2025), biocrates introduced the MxP® Quant 1000 kit, designed to deliver comprehensive quantitative coverage of metabolic biomarkers (up to 1,881 per sample) from small sample volumes, greatly enhancing metabolite profiling for chronic disease, oncology and systems biology research.
The kit supports deep biochemical pathway coverage with high precision, facilitating advanced quantitative metabolomics research and clinical applications.

Metabolon launches integrated microbiome-metabolomics research solution
On April 29, 2025, Metabolon, Inc. announced a new microbiome research solution combining a microbiome metabolite panel with metagenomics sequencing and bioinformatics tools, enabling deeper functional insights into microbiome-host metabolic interactions.
Metabolon enhances multiomics biomarker discovery tools
In Feb 2025, Metabolon expanded its Integrated Bioinformatics Platform with powerful new multiomics biomarker discovery capabilities including predictive modeling and pathway analysis to support more comprehensive phenotype interpretation.

✅ 3. R&D & Scientific Advancements
Landmark Population Health Metabolomics Study
In Nov 2025, Metabolon announced that its Global Discovery Panel was selected to analyze 62,000 veteran samples from the Million Veteran Program (MVP) one of the largest multiomics population health datasets ever assembled underscoring the growing role of metabolomics in large-scale research.
Metabolomics cited extensively in top research
Metabolon's metabolomics services have now been cited in more than 4,000 peer-reviewed publications across high-impact scientific journals, reflecting widespread integration of metabolomics in cutting-edge biomedical research.

Segments Covered in the Metabolomics Market:
By Product and Services
The market is segmented into detection techniques 40%, separation techniques 35%, and bioinformatics tools & services 25%, with detection techniques dominating due to widespread use of mass spectrometry (MS) and nuclear magnetic resonance (NMR) for accurate metabolite identification and quantification. Separation techniques such as liquid chromatography and gas chromatography remain essential for sample preparation and compound resolution. Bioinformatics tools and services are witnessing rapid growth as metabolomics generates large datasets requiring advanced data analysis, pathway mapping, and AI-driven interpretation. Increasing investment in omics research supports segment expansion.

By Application
Applications include biomarker & drug discovery 30%, nutrigenomics 20%, personalized medicine 20%, toxicology testing 15%, and others 15%, with biomarker & drug discovery leading due to extensive utilization of metabolomics in pharmaceutical R&D and precision drug development. Nutrigenomics is expanding with growing focus on diet-related health optimization. Personalized medicine adoption is rising as metabolomics supports patient-specific treatment strategies. Toxicology testing remains critical for safety assessment in pharmaceuticals, chemicals, and environmental studies.

By Indication
Indications comprise cancer 35%, neurological disorders 20%, cardiovascular disorders 15%, inborn errors of metabolism 15%, and others 15%, with cancer dominating due to extensive research into metabolic reprogramming for early diagnosis, prognosis, and therapy monitoring. Neurological disorders are gaining traction as metabolomics aids biomarker discovery for complex CNS diseases. Cardiovascular applications benefit from preventive diagnostics, while inborn errors of metabolism remain a core clinical application in newborn screening and rare disease management.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=metabolomics-market?sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Analysis
North America - 40% Share
North America leads with 40% share driven by strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, and high adoption of metabolomics technologies across the U.S. and Canada. Drug discovery and cancer research dominate applications. Significant funding, academic-industry collaborations, and technological innovation accelerate market growth.

Europe - 25% Share
Europe accounts for 25% share supported by robust academic research, government-funded healthcare programs, and growing focus on precision medicine across Germany, the UK, and France. Biomarker discovery and clinical research are key application areas. Favorable regulatory frameworks and collaborative research initiatives drive steady market expansion.

Asia Pacific - 20% Share
Asia Pacific holds 20% share driven by increasing pharmaceutical R&D, expanding healthcare infrastructure, and rising adoption of omics technologies in China, Japan, and India. Nutrigenomics and toxicology testing show strong growth. Government research funding and growing awareness of preventive healthcare support regional development.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.